Perennial Investment Advisors LLC Purchases 272 Shares of Thermo Fisher Scientific Inc. $TMO

Perennial Investment Advisors LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 22.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,463 shares of the medical research company’s stock after buying an additional 272 shares during the period. Perennial Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $593,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of the company. Revolve Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after buying an additional 20 shares during the last quarter. Lafayette Investments Inc. increased its position in shares of Thermo Fisher Scientific by 2.4% in the 2nd quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock valued at $376,000 after acquiring an additional 22 shares during the period. Rossmore Private Capital lifted its position in Thermo Fisher Scientific by 0.5% during the 1st quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock worth $2,315,000 after acquiring an additional 24 shares during the period. FARMERS & MERCHANTS TRUST Co OF LONG BEACH grew its stake in Thermo Fisher Scientific by 3.1% during the 2nd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company’s stock valued at $326,000 after purchasing an additional 24 shares during the last quarter. Finally, Somerville Kurt F raised its stake in shares of Thermo Fisher Scientific by 1.6% in the second quarter. Somerville Kurt F now owns 1,605 shares of the medical research company’s stock worth $651,000 after purchasing an additional 25 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the topic of several recent research reports. Hsbc Global Res lowered Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a report on Tuesday, September 2nd. William Blair began coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating on the stock. Cowen reissued a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Finally, JPMorgan Chase & Co. raised their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Nineteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $601.65.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $576.01 on Wednesday. The business has a 50-day moving average of $531.35 and a 200-day moving average of $470.43. The stock has a market capitalization of $216.41 billion, a price-to-earnings ratio of 33.28, a PEG ratio of 3.27 and a beta of 0.82. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.Thermo Fisher Scientific’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the business posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share repurchase plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity

In related news, VP Lisa P. Britt sold 1,058 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total value of $622,379.08. Following the completion of the sale, the vice president directly owned 13,087 shares of the company’s stock, valued at $7,698,558.62. The trade was a 7.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $574.15, for a total value of $229,660.00. Following the completion of the transaction, the executive vice president directly owned 21,152 shares of the company’s stock, valued at approximately $12,144,420.80. The trade was a 1.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 51,845 shares of company stock valued at $28,956,952. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.